Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401320 | 0.92 | GPR119 (0.48) | GPR119P2RX3RORCP2RX2CNR2 | |
| SCHEMBL6157116 | 0.88 | GPR119 (0.48) | GPR119RORCKDM4EPKMP2RX7 | |
| SCHEMBL6156309 | 0.83 | GPR119 (0.45) | GPR119RORCKDM4EPKMP2RX7 | |
| SCHEMBL6147993 | 0.77 | GPR119 (0.50) | GPR119KDM4EPKMP2RX7 | |
| SCHEMBL13834740 | 0.77 | BRD4 (0.48) | GPR119KDM4EPKM | |
| SCHEMBL2029083 | 0.77 | BRD4 (0.48) | GPR119KDM4EPKM | |
| SCHEMBL1333790 | 0.75 | CNR2 (0.56) | P2RX3CNR2 | |
| SCHEMBL13264168 | 0.75 | CNR2 (0.56) | P2RX3CNR2 | |
| SCHEMBL3867936 | 0.75 | FPR2 (0.41) | GPR119P2RX3RORCKDM4EPKM | |
| Hydrochloric Acid SCHEMBL6149148 | 0.74 | CNR2 (0.44) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
| EP-1495044-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. Uriach y Compania S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003084984-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. URIACH Y COMPANIA S.A. (ES) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | GPR119 789/4885P2RX3 430/4885RORC 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.